Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin

There is a broad range of factor products approved in Germany for haemophilia A treatment. Since the introduction of recombinant coagulation factor VIII (FVIII) products in the 1990s, there has been substantial debate whether there is a difference in inhibitor incidence between single FVIII products...

Descripción completa

Detalles Bibliográficos
Autores principales: Keipert, Christine, Drechsel-Bäuerle, Ursula, Oberle, Doris, Müller-Olling, Mirco, Hilger, Anneliese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795862/
https://www.ncbi.nlm.nih.gov/pubmed/33396748
http://dx.doi.org/10.3390/ijerph18010225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795862/
https://www.ncbi.nlm.nih.gov/pubmed/33396748
http://dx.doi.org/10.3390/ijerph18010225

Ejemplares similares